Plasfer, a preclinical-stage biotechnology company developing novel platelets-based therapeutics in various therapeutic areas, announced the appointment of Rosario Billetta as Chief Operating Officer to advance its company operations. In this role, Dr. Billetta will support the Company’s technology platform development and therapeutic programs operations, as well as be a significant contributor to corporate strategy in support of business operations.
Dr. Billetta most recently served as the Chief Technology Officer of Abilita Bio, Inc., a biotechnology company whose proprietary technology platform leverages directed evolution to identify enhanced target variants known as Enabled Membrane Proteins (EMPs). This platform focuses on enabling the discovery and development of drugs targeting challenging membrane proteins, including G Protein-Coupled Receptors (GPCRs) and ion channels.
Dr. Billetta is a platform technology development expert with over 30 years of experience, based in San Diego, CA, USA. Extensive hands-on experience in the development of preclinical and early clinical development (Phase-I and Phase-II) programs. He has served in executive positions in various biotech companies in the US and has BD and IP strategy experience. Previously, Dr. Billetta held positions as an Associate Professor of Immunology at the School of Medicine-U. Chile and as an Assistant Professor at the University of California, School of Medicine, San Diego, CA, USA.
“Plasfer represents an ideal opportunity to apply my relevant skill set at an important inflection point in the Company’s evolution in bringing promising, proprietary programs to treat cancer into human proof-of-concept studies in the near-term,” said Dr. Billetta. “I am genuinely excited to collaborate with the team at Plasfer as we collectively work to unlock the transformative potential of Plasfer’s platelets-based technology. Our goal is to bring disease-modifying, pioneering therapies to the market for the benefit of patients and to significantly advance the field of cancer therapy.”
